Brain HealthHow the RAGE Receptor Drives Parkinson's Dementia Through Silent Inflammation
Parkinson's disease frequently progresses from mild memory lapses to severe dementia, but the molecular bridges connecting protein aggregates, brain inflammation, and synaptic failure have remained unclear. This review identifies the receptor for advanced glycation end products — RAGE — as a central hub in that process. RAGE binds toxic proteins like alpha-synuclein, amyloid-beta, and tau, then activates at least four damaging cascades: a hyperinflammatory microglial response, intracellular inflammation via a RAGE-RIPK1 complex, active transport of amyloid-beta across the blood-brain barrier, and direct disruption of synaptic plasticity before neurons even die. Critically, protective soluble RAGE is depleted in dementia patients, making the RAGE axis a promising biomarker and drug target. Interventions such as RAGE-RIPK1 uncoupling peptides and sRAGE enhancement may intercept cognitive decline early in disease.
